ERBB2 and breast carcinoma: Nanobody-conjugated polymersomes and non-targeted nanoparticles were tested for binding to HER2-positive breast cancer cells utilizing confocal microscopy and flow cytometry, and the results illustrated that anti-HER2-VHH-functionalized PEO-b-PCL polymersomes target HER2-overexpressing breast cancer cell lines.